The Longevity Podcast: Alzheimer's and Brain Health Research

AI-hosted deep dives into the latest Alzheimer's, dementia and brain health research, curated by Dr. Dung Trinh. Each episode breaks down a recent study or topic, such as diet, sleep, exercise, heart health, biomarkers, early detection and new treatments. We explain what the science says and what it may mean for staying sharp as we age. Episodes are discussions generated with AI hosts. Every episode cites its sources so you can read the original research yourself. This podcast is for education only and is not medical advice. Talk with your doctor about your own health.

The Longevity Podcast: Alzheimer's and Brain Health Research is a health podcast hosted by Dung Trinh, with 404 episodes on record and a Required Pod Score of 80.

Dung Trinh hosts The Longevity Podcast: Alzheimer's and Brain Health Research, a health show with 404 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  The Longevity Podcast: Alzheimer's and Brain Health Research

  Dementia Safety Risks: Medication Errors Top China Study

  Oct 4, 202646 min

  Send us Fan Mail A China-wide survey of 1,057 older adults with Alzheimer's or related cognitive impairment found 73.5% had at least one safety incident in the past year, and over a third reported three or more. Medication errors and verbal aggression were the most common, followed by falls and physical aggression. Medication errors and getting lost also sat at the center of how different incidents linked together across care settings and regions. Source: Zhou Y, et al., Mapping the nature, type, and association network of safety incidents among individuals with cognitive impairment in China: a large-scale multicenter cross-sectional study, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100606 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

  ListenShow Notes
• 

  The Longevity Podcast: Alzheimer's and Brain Health Research

  Alzheimer's Drug Safety: Why Blood Thinner Exclusions Matter

  Oct 3, 202620 min

  Send us Fan Mail A letter in JPAD argues that a reported safety advantage for an anti-amyloid antibody drug, in a European-label subgroup of its phase 3 trial, may largely reflect excluding patients on blood thinners. About one in four people with Alzheimer's take those medicines in real-world data, so the subgroup findings may not apply in everyday practice. Source: Ijaz A, Mohyudin G, The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100628 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

  ListenShow Notes
• 

  The Longevity Podcast: Alzheimer's and Brain Health Research

  Dementia Risk Knowledge: Why Recognition Isn't Enough

  Oct 2, 202619 min

  Send us Fan Mail A letter responds to a large review of public dementia risk awareness, arguing that recognizing a risk factor is not the same as knowing what to do about it. The authors urge surveys to measure actionable knowledge, whether risks are personal habits or policy problems, and to separate fear and stigma from true risk perception. Source: Xie Z, Su J, Liao T, Beyond recognition: Refining the assessment of public knowledge and risk perception in dementia prevention, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100602 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

  ListenShow Notes
• 

  The Longevity Podcast: Alzheimer's and Brain Health Research

  Donanemab EU Label: Why Subgroup Data Matter for Alzheimer's Drugs

  Oct 1, 202622 min

  Send us Fan Mail When Europe approved donanemab and lecanemab, the label was narrower than the trials: early Alzheimer's, APOE ε4 non-carriers or heterozygotes, plus extra exclusions. This editorial walks through why EU-eligible subgroup analyses matter—and how Jessen's TRAILBLAZER-ALZ 2 re-analysis shows benefit and safety still hold (even improve a bit) in the patients clinicians actually treat. Source: Grimmer T, From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100665 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

  ListenShow Notes
• 

  The Longevity Podcast: Alzheimer's and Brain Health Research

  Tau Clearance in Alzheimer's: Brain Cells That Shuttle Toxic Protein

  Sep 30, 202622 min

  Send us Fan Mail How does toxic Tau leave the brain? In this editorial, Vincent Prévot and colleagues spotlight tanycytes—specialized cells lining the third ventricle that shuttle Tau from cerebrospinal fluid into the blood. In Alzheimer's disease these cells are fragmented and their transport genes look dysregulated, which may worsen Tau buildup and open a new therapeutic angle. Source: Prévot V, Schwaninger M, Nogueiras R, Rasika S, Tau-ing and fro-ing: the tanycytic shuttle in neurodegeneration, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100643 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.